Blood, Vol. 111, Issue 10, 4979-4985, May 15, 2008
Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: Molecular and Clinical Markers for the Diagnosis and Management of Type 1 VWD (MCMDM-1VWD)
Blood Haberichter et al. 111: 4979
Supplemental materials for: Haberichter et al
European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD)
Castaman, Giancarlo1, Budde, Ulrich2, Peake, Ian3, Goodeve, Anne3, Rodeghiero, Francesco1, Federici, Augusto B.4, Batlle, Javier5, Meyer, Dominique6, Mazurier, Claudine7, Goudemand, Jenny8, Eikenboom Jereon9, Schneppenheim, Reinhard10, , Ingerslev, Jorgen11, Vorlova, Zdena12, Habart, David12, Holmberg, Lars13, Lethagen, Stefan13, Pasi, John14, Hill, Frank G.H.15
1 San Bortolo Hospital,Vicenza, Italy
2 Coagulation Laboratory, Hamburg, Germany
3 University of Sheffield, Sheffield, UK
4 IRCCS Foundation Maggiore Hospital, University of Milan, Milan, Italy
5 Hospital Teresa Herrera, La Coruna, Spain
6 INSERM, Paris, France
7 LFB, Lille, France
8 University of Lille, Lille, France
9 Leiden University Medical Center, Leiden, Netherlands
10 University Medical Center Hamburg-Eppendorf, Department of Pediatric Hematology and Oncology, Hamburg, Germany
11 University Hospital Skejby, Aarhus, Denmark
12 Institute of Hematology and Blood Transfusion, Prague, Czech Republic
13 University of Lund, Malmo, Sweden, Copenhagen University, Denmark
14 Barts and The London, Queen Mary University of London, UK
15 Children’s Hospital, Birmingham, UK